Advancing Our Clinical Perspectives in Haematology: What Is Your Approach?

Summary of presentations from the 11th New Horizons in Haematology conference which took place on 11th March 2016 and was webcast live to moderated audiences in Hong Kong, Italy, Japan, Russia, South Africa, and Spain, and to individuals throughout the world

Moderator: Sarah Jarvis1
Speakers: Gunnar Birgegård,2 Tamara Lado Cives,3 Sélim Aractingi,4 Chiaki Nakaseko,5 Claire Harrison,6 Melania Moreno Vega,7 Jean‑Jacques Kiladjian,8 Salah Alimam,9 Manuel Martinez‑Sellés10

1. Primary Care Physician and Healthcare Reporter, UK
2. Division of Medical Sciences, Haematology, Uppsala University, Uppsala, Sweden
3. Servicio de Hematología Clinica, Hospital Clínico Universitario de Valladolid, Valladolid, Spain
4. Department of Dermatology, Cochin Hôpital, Paris, France
5. Department of Hematology, Chiba University Hospital, Chiba, Japan
6. Department of Cancer and Haematology, Guy’s and St. Thomas’ Hospital, London, UK
7. Negrin University Hospital, Gran Canaria, Las Palmas, Spain
8. Clinical Investigations Centre, Hôpital Saint‑Louis, Paris, France
9. Department of Haematology, Guy’s and St. Thomas’ Hospital, London, UK
10. Department of Cardiology, Gregorio Marañon Hospital, Madrid, Spain

Disclosure: Sarah Jarvis has no conflicts of interests to disclose. Gunnar Birgegård has received speaker’s fees/honoraria from Shire and Vifor Pharma. Tamara Lado Cives has no conflicts of interest to disclose.  Sélim Aractingi has received research support from Leo Pharma, speaker’s fees/honoraria from Shire, Novartis, and AbbVie and has served on advisory boards for Shire and Novartis. Chiaki Nakaseko has  received research support from Bristol‑Myers Squibb, Pfizer, Kyowa‑Hakko Kirin, Takeda, Chugai, Otsuka, Shionogi, and Asahikasei‑Pharm and speaker’s fees/honoraria from Pfizer, Celgene, Bristol‑Myers Squibb,  and Shire. Claire Harrison has received research support from Novartis, speaker’s fees/honoraria from Novartis, Shire, CTI, Baxalta, Gilead, and Incyte and has served on advisory boards for CTI, Baxalta, and Novartis. Melania Moreno Vega has no conflicts of interests to disclose. Jean‑Jacques Kiladjian has received research support from Novartis, speaker’s fees/honoraria from Novartis, Shire, and AOP Orphan and has served on advisory boards for Novartis, Shire, and AOP Orphan. Samah Alimam has no conflicts of  interests to disclose. Manuel Martinez‑Sellés has received research support from Servier, Novartis, and  Pfizer, speaker’s fees/honoraria from Servier, Shire, Novartis, and Pfizer and has served on advisory boards for Shire.
Acknowledgements: The 11th New Horizons in Haematology conference was initiated, organised, and  funded by Shire. Medical writing assistance was funded by Shire. The views and opinions expressed are those of the authors as expressed during the conference and not necessarily those of Shire.
Citation: EMJ Hematol. 2016;4[Suppl 9]:2‑9

Meeting Summary

The 11th New Horizons in Haematology (NHH11) conference was moderated by Dr Sarah Jarvis, healthcare reporter and television presenter, and was delivered in the format of a live, interactive, online meeting. Prof Gunnar Birgegård opened the conference with a presentation on the evolution of essential thrombocythaemia (ET) disease, Prof Sélim Aractingi described the incidence of skin lesions in myeloproliferative neoplasms (MPN), Prof Claire Harrison discussed key aspects in women’s health when managing ET including pregnancy, Prof Jean‑Jacques Kiladjian covered the management of elderly patients with ET, and Dr Manuel Martínez‑Sellés concluded the meeting by emphasising the importance of identifying and managing cardiovascular (CV) risk factors in ET. Dr Tamara Lado Cives, Prof Chiaki Nakaseko, Dr Melania Moreno Vega, and Dr Samah Alimam each shared a case study after the main presentations.

Download (PDF, 123KB)

Keywords: ,

Comments are closed.